See more : Orex Minerals Inc. (REX.V) Income Statement Analysis – Financial Results
Complete financial analysis of Dicerna Pharmaceuticals, Inc. (DRNA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Dicerna Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Packaging Corporation of America (0KEZ.L) Income Statement Analysis – Financial Results
- Monro, Inc. (MNRO) Income Statement Analysis – Financial Results
- Tekumo, Inc. (TKMO) Income Statement Analysis – Financial Results
- Curative Biotechnology, Inc. (CUBT) Income Statement Analysis – Financial Results
- Wellbiotec Co., Ltd. (010600.KS) Income Statement Analysis – Financial Results
Dicerna Pharmaceuticals, Inc. (DRNA)
About Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts. As of December 27, 2021, Dicerna Pharmaceuticals, Inc. operates as a subsidiary of Novo Nordisk A/S.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 164.31M | 23.90M | 6.18M | 2.28M | 295.00K | 184.00K | 0.00 | 0.00 | 7.02M | 7.91M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 164.31M | 23.90M | 6.18M | 2.28M | 295.00K | 184.00K | 0.00 | 0.00 | 7.02M | 7.91M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 100.00% | 100.00% |
| Research & Development | 205.38M | 109.34M | 45.71M | 36.98M | 41.69M | 43.97M | 29.45M | 11.56M | 11.57M | 10.71M |
| General & Administrative | 72.13M | 42.75M | 21.69M | 25.88M | 18.35M | 19.24M | 15.65M | 5.82M | 4.70M | 4.82M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 72.13M | 42.75M | 21.69M | 25.88M | 18.35M | 19.24M | 15.65M | 5.82M | 4.70M | 4.82M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 277.52M | 152.09M | 67.40M | 62.86M | 60.04M | 63.21M | 45.10M | 17.38M | 16.27M | 15.52M |
| Cost & Expenses | 277.52M | 152.09M | 67.40M | 62.86M | 60.04M | 63.21M | 45.10M | 17.38M | 16.27M | 15.52M |
| Interest Income | 6.01M | 7.54M | 2.10M | 539.00K | 235.00K | 188.00K | 63.00K | 4.00K | 2.00K | 3.00K |
| Interest Expense | 20.00K | 3.00K | 603.00K | 0.00 | 0.00 | 0.00 | 199.00K | 952.00K | 1.34M | 997.00K |
| Depreciation & Amortization | 2.22M | 1.25M | 774.00K | 778.00K | 840.00K | 727.00K | 848.00K | 523.00K | 551.00K | 474.00K |
| EBITDA | -110.51M | -119.20M | -87.48M | -59.27M | -58.67M | -62.11M | -46.89M | -17.04M | -8.23M | -7.09M |
| EBITDA Ratio | -67.26% | -498.67% | -1,416.39% | -2,602.99% | -19,889.15% | -33,756.52% | 0.00% | 0.00% | -117.29% | -89.59% |
| Operating Income | -113.21M | -128.19M | -61.22M | -60.59M | -59.75M | -63.03M | -45.10M | -17.38M | -9.25M | -7.61M |
| Operating Income Ratio | -68.90% | -536.25% | -991.26% | -2,660.83% | -20,253.56% | -34,253.80% | 0.00% | 0.00% | -131.86% | -96.27% |
| Total Other Income/Expenses | 461.00K | 7.73M | -27.63M | 539.00K | 235.00K | 188.00K | -2.84M | -1.14M | -871.00K | -943.00K |
| Income Before Tax | -112.75M | -120.46M | -88.85M | -60.05M | -59.51M | -62.84M | -47.94M | -18.52M | -10.12M | -8.56M |
| Income Before Tax Ratio | -68.62% | -503.93% | -1,438.68% | -2,637.15% | -20,173.90% | -34,151.63% | 0.00% | 0.00% | -144.28% | -108.19% |
| Income Tax Expense | 481.00K | 7.73M | -27.03M | 539.00K | 235.00K | 188.00K | -2.64M | -188.00K | 471.00K | 54.00K |
| Net Income | -112.75M | -120.46M | -88.85M | -60.05M | -59.51M | -62.84M | -47.94M | -18.52M | -10.12M | -8.56M |
| Net Income Ratio | -68.62% | -503.93% | -1,438.68% | -2,637.15% | -20,173.90% | -34,151.63% | 0.00% | 0.00% | -144.28% | -108.19% |
| EPS | -1.51 | -1.76 | -1.60 | -2.90 | -2.87 | -3.09 | -2.98 | -1.11 | -4.95 | -0.11 |
| EPS Diluted | -1.51 | -1.76 | -1.60 | -2.90 | -2.87 | -3.09 | -2.98 | -1.11 | -4.95 | -0.11 |
| Weighted Avg Shares Out | 74.52M | 68.43M | 55.62M | 20.72M | 20.72M | 20.32M | 16.07M | 16.63M | 2.05M | 77.91M |
| Weighted Avg Shares Out (Dil) | 74.52M | 68.43M | 55.62M | 20.72M | 20.72M | 20.32M | 16.07M | 16.63M | 2.05M | 77.91M |
Dicerna A Buy On Long-Term Potential
Dicerna Pharmaceuticals (DRNA) CEO Doug Fambrough on Q1 2021 Results - Earnings Call Transcript
Dicerna Pharmaceuticals (DRNA) Reports Q1 Loss, Lags Revenue Estimates
Dicerna Announces First Quarter 2021 Financial Results and Provides a Business Update
Dicerna Announces First Quarter 2021 Financial Results and Provides a Business Update
Dicerna to Report First Quarter 2021 Financial Results on May 6, 2021
Dicerna to Report First Quarter 2021 Financial Results on May 6, 2021
Dicerna Sells Oxlumo Royalty Interest To Royalty Pharma For $180M Upfront
Dicerna Sells OXLUMO™ (lumasiran) Royalty Interest to Royalty Pharma for Up to $240 Million
Dicerna Sells OXLUMO™ (lumasiran) Royalty Interest to Royalty Pharma for Up to $240 Million
Source: https://incomestatements.info
Category: Stock Reports